Delgocitinib for treating moderate to severe chronic hand eczema

  • Technology appraisal guidance
  • TA1107
  • Published: 
Download guidance (PDF)

2 Information about delgocitinib

Marketing authorisation indication

2.1

Delgocitinib (Anzupgo, Leo Pharma) is indicated for 'the treatment of moderate to severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate'.

Dosage in the marketing authorisation

Price

2.3

The list price of delgocitinib cream (20 mg per 1 g) is £595 per 60‑g tube (excluding VAT; BNF online, accessed May 2025).

2.4

Costs may vary in different settings because of negotiated procurement discounts.

2.5

The company has a commercial arrangement. This makes delgocitinib available to the NHS with a discount. The size of the discount is commercial in confidence.

Carbon Reduction Plan

2.6

For information, Leo Pharma did not disclose its Carbon Reduction Plan for UK carbon emissions.